Celyad Oncology SA
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$8,448,000 and profit margin reached -8282%. Total operating expenses were $8,490,000.

Profit Margin

Celyad Oncology SA (NASDAQ:CYAD): Profit margin
2014 146K -16.45M -11269.18%
2015 3K -29.11M -970466.67%
2016 8.52M -23.60M -276.97%
2017 3.54M -56.39M -1593.08%
2018 3.11M -37.42M -1201.51%
2019 6K -28.63M -477200%
2020 5K -17.50M -350020%
2021 0 -26.51M
2022 0 -40.93M
2023 102K -8.44M -8282.35%

CYAD Income Statement (2014 โ€“ 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue
Revenue
102K005K6K3.11M3.54M8.52M3K146K
Cost of revenue
69K00000515K53K6.38M115K
Gross profit
33K005K6K3.11M3.02M8.47M-6.37M31K
Operating exp.
Research and development
4.66M18.92M20.77M21.59M25.23M24.94M22.90M27.67M5.89M15.86M
Selling and marketing
215K00454K0676K761K728K891K394K
Total operating expenses
8.49M20.26M26.90M26.24M29.37M34.50M29.62M34.72M29.67M19.91M
Operating income
-8.45M-40.85M-26.39M-26.23M-29.37M-38.17M-52.87M-25.60M-29.67M-16.43M
Other income (expenses), net
-54K-13K-111K-217K733K743K-3.52M1.99M558K-16K
Income before tax
-8.51M-40.87M-26.50M-17.20M-28.64M-37.42M-56.39M-23.61M-29.11M-16.45M
Income tax expense
-191K65K10K297K-8K805K-1K-6K-55K-2.48M
Net income
-8.44M-40.93M-26.51M-17.50M-28.63M-37.42M-56.39M-23.60M-29.11M-16.45M
Earnings per share
Basic EPS
-0.33-1.81-1.7-1.26-2.29-3.36-5.86-2.53-3.43-2.44
Diluted EPS
-0.33-1.81-1.7-1.26-2.29-3.36-5.86-2.53-3.43-2.44
Data sourceData sourceData sourceData sourceData source